Madrigal Pharmaceuticals (MDGL) Shares Outstanding (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly Shares Outstanding (Entity) of $29.1 million for Q2 2026, up 31.16% year-over-year from $22.2 million in Q2 2025, and little changed quarter-over-quarter from $29.0 million in Q1 2026.
Madrigal Pharmaceuticals (MDGL) Shares Outstanding (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported Shares Outstanding (Entity) for 17 consecutive years, with $29.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Shares Outstanding (Entity) rose 31.16% year-over-year to $29.1 million; the TTM figure through Jun 2026 stood at $29.1 million (up 31.16% YoY), while the FY2025 annual figure was $22.8 million, up 3.81% from the prior year.
- Shares Outstanding (Entity) held at $29.1 million in Q2 2026 per MDGL's latest filing, from $29.0 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $29.1 million in Q2 2026 and bottomed at $17.1 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $20.9 million across 5 years, with a median of $20.3 million in 2023.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) rose 1.44% — and 2026, when it jumped 31.16%.
- Madrigal Pharmaceuticals' Shares Outstanding (Entity) stood at $18.1 million in 2022, then grew by 14.26% to $20.7 million in 2023, then gained by 6.38% to $22.0 million in 2024, then increased by 3.81% to $22.8 million in 2025, then advanced by 27.59% to $29.1 million in 2026.
- Business Quant data shows MDGL's Shares Outstanding (Entity) at $29.1 million in Q2 2026, $29.0 million in Q1 2026, and $22.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Madrigal Pharmaceuticals | 14.79 Bn | 13.95 Bn | - | 29.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.15 Mn |
| Mar 31, 2026 | 29.03 Mn |
| Dec 31, 2025 | 22.43 Mn |
| Sep 30, 2025 | 22.48 Mn |
| Jun 30, 2025 | 22.21 Mn |
| Mar 31, 2025 | 22.09 Mn |
| Dec 31, 2024 | 21.27 Mn |
| Sep 30, 2024 | 21.75 Mn |
| Jun 30, 2024 | 21.40 Mn |
| Mar 31, 2024 | 20.00 Mn |
| Dec 31, 2023 | 18.69 Mn |
| Sep 30, 2023 | 18.48 Mn |
| Jun 30, 2023 | 18.31 Mn |
| Mar 31, 2023 | 18.19 Mn |
| Dec 31, 2022 | 17.14 Mn |
| Sep 30, 2022 | 17.10 Mn |
| Jun 30, 2022 | 17.10 Mn |
| Mar 31, 2022 | 17.10 Mn |
| Dec 31, 2021 | 16.54 Mn |
| Sep 30, 2021 | 16.64 Mn |